What do systematic reviews say?

Maintenance of initial therapeutic response of at least 30% pain intensity reduction over baseline and continued treatment at 13 or 26 weeks (equivalent to 'moderate benefit') · adults with fibromyalgia enrolled in EERW studies

Participant‐reported pain relief of 30% or greater · adults with moderate or severe pain associated with postherpetic neuralgia

Participant‐reported pain relief of 30% or greater · adults with moderate or severe pain associated with painful diabetic neuropathy

Participant‐reported pain relief of 30% or greater · adults with moderate or severe pain associated with painful diabetic neuropathy

Participant‐reported pain relief of 30% or greater · adults with moderate or severe pain associated with postherpetic neuralgia